Fig. 5. Co-treatment with GroA and AG-825 reduces ErbB2 activation.

SKBR3 and MCF7–ErbB2 (ErbB2-overexpressing clones) were treated with GroA, AG-825 or both, as indicated, and ErbB2 phosphorylation levels were determined using anti-phospho-ErbB2 antibody (means ± SD; *p < 0.05, **p < 0.01, ***p < 0.005—co-treated cells compared to untreated or single-agent treated cells; ^p < 0.05, ^^^p < 0.005—GroA/AG-825 treated cells compared to untreated cells; n > 3). Inset, immunoblot analysis of ErbB2 expression in MCF7–ErbB2 cells compared with naïve MCF7 cells; numbers below bands indicate average fold induction of naïve MCF7 cells